从指南更新看二甲双胍在2型糖尿病药物治疗中的地位

Status of metformin in the drug treatment for type 2 diabetes mellitus based on the update of guideline

二甲双胍作为传统经典的口服降糖药物,是临床使用最广泛的降糖药物之一。因其降糖疗效确切,且兼顾安全性和耐受性,目前不断更新的国内外糖尿病指南仍均推荐其作为2型糖尿病(type 2 diabetes mellitus,T2DM)治疗的一线药物。越来越多的指南和证据表明,其在T2DM患者合并心血管和肾脏疾病,甚至在合并认知功能障碍的治疗中具有显著的获益;在T2DM合并新型冠状病毒肺炎(corona virus disease 2019,COVID-19)的治疗中发现,其可明显降低此类患者的病死率和住院率。未来,对于预防糖尿病前期患者进展为糖尿病,二甲双胍有望谱写新篇章。

Metformin,as a traditional classical oral hypoglycemic drug,is one of the most widely used hypoglycemic drugs in clinical practice. Because of its definite hypoglycemic effect as well as safety and tolerability,the continuously updated domestic and foreign guidelines for diabetes recommend it as a first-line drug for the treatment of type 2 diabetes(T2DM).More and more guidelines and evidence have shown that it has significant benefit in the management of T2DM patients with cardiovascular,renal diseases and even cognitive dysfunction. In the treatment of T2DM patients with Corona Virus Disease2019(COVID-19),it has been found that metformin can significantly reduce the mortality and hospitalization rate of such patients. In the future,metformin is expected to compose a new chapter for preventing prediabetes from turning into diabetes.